Pharma portfolios can create powerful opportunities, but without clear positioning, brands can end up competing with each other.

In this episode, Lumanity’s Jakub Kaczor, VP, Strategy Consulting, and Peter Smith, SVP, Strategy Consulting, discuss the complexities of portfolio positioning in the pharmaceutical industry. The guests explain that while a focused R&D strategy drives innovation, it also creates a paradox where a company’s own assets can end up competing against each other in the same disease area. To mitigate internal rivalry and maximize commercial potential, they advise companies to begin co-positioning early in clinical development by mapping distinct patient segments and study endpoints. Ultimately, achieving portfolio success requires overcoming brand egos through a collaborative mindset, establishing clear governance under a dedicated portfolio owner, and designing strategies that anticipate the future competitive landscape.

Tune in to learn how pharma teams can reduce internal competition, improve customer clarity, and build stronger portfolios that serve both patients and commercial goals!

Listen Now

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Sign me up to receive regular insights from Lumanity